Wells Fargo's Analyst Discusses Valeant's 'Apology Tour' By: Benzinga via Benzinga April 27, 2016 at 14:58 PM EDT David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back ... Read More >> Related Stocks: Valeant Pharmaceuticals International, Inc.